

WHAT IS CLAIMED IS:

1. An isolated or recombinant polynucleotide encoding an antigenic polypeptide comprising:
- 5 a) at least 17 contiguous amino acids from the mature polypeptide from SEQ ID NO: 2;
- b) at least 17 contiguous amino acids from the mature polypeptide from SEQ ID NO: 4;
- 10 c) at least 17 contiguous amino acids from the mature polypeptide from SEQ ID NO: 6;
- d) at least 17 contiguous amino acids from the mature polypeptide from SEQ ID NO: 8;
- e) at least 17 contiguous amino acids from the mature polypeptide from SEQ ID NO: 13;
- 15 f) at least 17 contiguous amino acids from the polypeptide from SEQ ID NO: 15;
- g) at least 17 contiguous amino acids from the polypeptide from SEQ ID NO: 17; or
- 20 h) at least 17 contiguous amino acids from the polypeptide from SEQ ID NO: 19.
2. The polynucleotide of Claim 1, encoding all of the polypeptide of:
- 25 a) mature SEQ ID NO: 2;
- b) mature SEQ ID NO: 4;
- c) mature SEQ ID NO: 6;
- d) mature SEQ ID NO: 8;
- e) mature SEQ ID NO: 13;
- f) SEQ ID NO: 15;
- 30 g) SEQ ID NO: 17; or
- h) SEQ ID NO: 19.
3. The polynucleotide of Claim 1, which hybridizes at 55° C, less than 500 mM salt, and 50% formamide to:
- 35 a) the mature polypeptide coding portion of SEQ ID NO: 1;

- 5 b) the mature polypeptide coding portion of SEQ ID NO: 3;
- c) the mature polypeptide coding portion of SEQ ID NO: 5;
- 10 d) the mature polypeptide coding portion of SEQ ID NO: 7;
- e) the mature polypeptide coding portion of SEQ ID NO: 12;
- f) the polypeptide coding portion of SEQ ID NO: 14;
- g) the polypeptide coding portion of SEQ ID NO: 16;
- or
- h) the polypeptide coding portion of SEQ ID NO: 18.

4. The polynucleotide of Claim 3, comprising:

- 15 a) at least 35 contiguous nucleotides of the mature coding portion of SEQ ID NO: 1;
- b) at least 35 contiguous nucleotides of the mature coding portion of SEQ ID NO: 3;
- 20 c) at least 35 contiguous nucleotides of the mature coding portion of SEQ ID NO: 5;
- d) at least 35 contiguous nucleotides of the mature coding portion of SEQ ID NO: 7;
- e) at least 35 contiguous nucleotides of the mature coding portion of SEQ ID NO: 12;
- 25 f) at least 35 contiguous nucleotides of the coding portion of SEQ ID NO: 14;
- g) at least 35 contiguous nucleotides of the coding portion of SEQ ID NO: 16; or
- 30 h) at least 35 contiguous nucleotides of the coding portion of SEQ ID NO: 18.

5. An expression vector comprising the polynucleotide of Claim 1.

- 35 6. A host cell containing the expression vector of Claim 5, including a eukaryotic cell.

Sub B2
Cont.

7. A method of making an antigenic polypeptide comprising expressing a recombinant polynucleotide of Claim 1.

5 8. A method for detecting a polynucleotide of Claim 1, comprising contacting said polynucleotide with a probe that hybridizes, under stringent conditions, to at least 25 contiguous nucleotides of:

- sub B27
cont.
- 10 a) the polynucleotide comprising the signal processed coding portion of SEQ ID NO: 1;
- b) the polynucleotide comprising the signal processed coding portion of SEQ ID NO: 3;
- c) the polynucleotide comprising the signal processed coding portion of SEQ ID NO: 5;
- 15 d) the polynucleotide comprising the signal processed coding portion of SEQ ID NO: 7;
- e) the polynucleotide comprising the signal processed coding portion of SEQ ID NO: 12;
- f) the polynucleotide comprising the coding portion of SEQ ID NO: 14;
- 20 g) the polynucleotide comprising the coding portion of SEQ ID NO: 16; or
- h) the polynucleotide comprising the coding portion of SEQ ID NO: 18;

25 to form a duplex, wherein detection of said duplex indicates the presence of said polynucleotide.

9. A kit for the detection of a polynucleotide of Claim 1, comprising a compartment containing a probe that
30 hybridizes, under stringent hybridization conditions, to at least 17 contiguous nucleotides of a polynucleotide of Claim 1 to form a duplex.

10. The kit of claim 9, wherein said probe is
35 detectably labeled.

11. A binding compound comprising an antibody binding site which specifically binds to:

- 5 a) at least 17 contiguous amino acids from the signal processed form of SEQ ID NO: 2;
- b) at least 17 contiguous amino acids from the signal processed form of SEQ ID NO: 4;
- c) at least 17 contiguous amino acids from the signal processed form of SEQ ID NO: 6;
- 10 d) at least 17 contiguous amino acids from the signal processed form of SEQ ID NO: 8;
- e) at least 17 contiguous amino acids from the signal processed form of SEQ ID NO: 13;
- f) at least 17 contiguous amino acids from SEQ ID NO: 15;
- 15 g) at least 17 contiguous amino acids from SEQ ID NO: 17; or
- h) at least 17 contiguous amino acids from SEQ ID NO: 19.

20 12. The binding compound of Claim 11, wherein:

- a) said antibody binding site is:
- 25 1) selectively immunoreactive with a polypeptide of the signal processed form of SEQ ID NO: 2;
- 2) selectively immunoreactive with a polypeptide of the signal processed form of SEQ ID NO: 4;
- 30 3) selectively immunoreactive with a polypeptide of the signal processed form of SEQ ID NO: 6;
- 4) selectively immunoreactive with a polypeptide of the signal processed form of SEQ ID NO: 8;
- 35 5) selectively immunoreactive with a polypeptide of the signal processed form of SEQ ID NO: 13;

sub B2
cont.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

5

- 6) selectively immunoreactive with a polypeptide of SEQ ID NO: 15;
- 7) selectively immunoreactive with a polypeptide of SEQ ID NO: 17;
- 8) selectively immunoreactive with a polypeptide of SEQ ID NO: 19; or

b) said binding compound is:

- 1) an antibody molecule;
- 2) a polyclonal antiserum;
- 3) detectably labeled;
- 4) sterile; or
- 5) in a buffered composition.

15

13. A method using the binding compound of Claim 11, comprising contacting said binding compound with a biological sample comprising an antigen, thereby forming a binding compound:antigen complex.

20

14. The method of Claim 13, wherein said biological sample is from a human, and wherein said binding compound is an antibody.

25

15. A detection kit comprising said binding compound of Claim 12, and:

- a) instructional material for the use of said binding compound for said detection; or
- b) a compartment providing segregation of said binding compound.

30

16. A substantially pure or isolated antigenic polypeptide, which binds to said binding composition of Claim 11, and further comprises at least 17 contiguous amino acids from:

35

- a) the signal processed polypeptide from SEQ ID NO: 2;
- b) the signal processed polypeptide from SEQ ID NO: 4;

sub B2
cont 10

- 5
- sub B2
cont.
- 10
- c) the signal processed polypeptide from SEQ ID NO: 6;
 - d) the signal processed polypeptide from SEQ ID NO: 8;
 - e) the signal processed polypeptide from SEQ ID NO: 13;
 - f) SEQ ID NO: 15;
 - g) SEQ ID NO: 17; or
 - h) SEQ ID NO: 19.

17. The polypeptide of Claim 16, which:

- 15
- 20
- 25
- 30
- a) comprises at least a fragment of at least 25 contiguous amino acid residues from a signal processed primate HDTEA84 protein;
 - b) comprises at least a fragment of at least 25 contiguous amino acid residues from a signal processed primate HSLJD37R protein;
 - c) comprises at least a fragment of at least 25 contiguous amino acid residues from a signal processed rodent RANKL protein; or
 - d) comprises at least a fragment of at least 25 contiguous amino acid residues from primate RANKL protein;
 - e) is a soluble polypeptide;
 - f) is detectably labeled;
 - g) is in a sterile composition;
 - h) is in a buffered composition;
 - i) binds to an sialic acid residue;
 - j) is recombinantly produced, or
 - k) has a naturally occurring polypeptide sequence.

18. The polypeptide of Claim 17, which:

- 35
- a) comprises at least 17 contiguous amino acids of the signal processed SEQ ID NO: 2;
 - b) comprises at least 17 contiguous amino acids of the signal processed SEQ ID NO: 4;

- 5 c) comprises at least 17 contiguous amino acids of
the signal processed SEQ ID NO: 6;
- d) comprises at least 17 contiguous amino acids of
the signal processed SEQ ID NO: 8;
- 10 e) comprises at least 17 contiguous amino acids of
the signal processed SEQ ID NO: 13;
- f) comprises at least 17 contiguous amino acids of
SEQ ID NO: 15;
- 15 g) comprises at least 17 contiguous amino acids of
SEQ ID NO: 17; or
- h) comprises at least 17 contiguous amino acids of
SEQ ID NO: 19.

19. A method of modulating a precursor cell
15 physiology or function comprising a step of contacting said
cell with:

- 20 a) a binding compound which binds to said polypeptide
of Claim 16;
- b) an HDTEA84 polypeptide;
- 25 c) an HSLJD37R polypeptide; or
- d) a RANKL polypeptide.

20. The method of Claim 19, wherein said contacting
is in combination with a TNF family ligand, or an
25 antagonist of said TNF family ligand.

sub B2
cont

100
99
98
97
96
95
94
93
92
91
90
89
88
87
86
85
84
83
82
81
80
79
78
77
76
75
74
73
72
71
70
69
68
67
66
65
64
63
62
61
60
59
58
57
56
55
54
53
52
51
50
49
48
47
46
45
44
43
42
41
40
39
38
37
36
35
34
33
32
31
30
29
28
27
26
25
24
23
22
21
20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1